{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T07:32:13Z","timestamp":1676273533232},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T00:00:00Z","timestamp":1337731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00380-012-0260-7","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T19:42:22Z","timestamp":1337715742000},"page":"442-452","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Masanori","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Inoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishiro","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,23]]},"reference":[{"key":"260_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2006.003","volume":"7","author":"C Ferrario","year":"2006","unstructured":"Ferrario C (2006) Role of angiotensin II in cardiovascular disease\u2014therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 7:3\u201314","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"260_CR2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"A Chobanian","year":"2003","unstructured":"Chobanian A, Bakris G, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560\u20132572","journal-title":"JAMA"},{"key":"260_CR3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrd2550","volume":"7","author":"C Jensen","year":"2008","unstructured":"Jensen C, Herold P, Brunner H (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7:339\u2013410","journal-title":"Nat Rev Drug Discov"},{"key":"260_CR4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","volume":"109","author":"M Azizi","year":"2004","unstructured":"Azizi M, Menard J (2004) Combined blockade of renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109:2492\u20132499","journal-title":"Circulation"},{"key":"260_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00380-009-1188-4","volume":"25","author":"K Omae","year":"2010","unstructured":"Omae K, Ogawa T, Nitta K (2010) Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease. Heart Vessels 25:203\u2013208","journal-title":"Heart Vessels"},{"key":"260_CR6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921\u2013927","journal-title":"Circulation"},{"key":"260_CR7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","volume":"37","author":"P Rossing","year":"1994","unstructured":"Rossing P, Hommel E, Smidt UM, Parving HH (1994) Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511\u2013516","journal-title":"Diabetologia"},{"key":"260_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2010.531","volume":"80","author":"RT Gansevoort","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Goresh J, the Chronic Kidney Disease Prognosis Consortium (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93\u2013104","journal-title":"Kidney Int"},{"key":"260_CR9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-154-1-201101040-00003","volume":"154","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, Quinn RR, Wiebe N, Hemmelgarn BR, the Alberta Kidney Disease Network (2011) Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease. Ann Intern Med 154:12\u201321","journal-title":"Ann Intern Med"},{"key":"260_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, Nahas MEL, Astor BC, Matsushita K, Gansevoort RT, Kasiske B, Eckardt KU (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 80:17\u201328","journal-title":"Kidney Int"},{"key":"260_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"JL Pool","year":"2007","unstructured":"Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination of valsartan. Am J Hypertens 20:11\u201320","journal-title":"Am J Hypertens"},{"key":"260_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370:221\u2013229","journal-title":"Lancet"},{"key":"260_CR13","doi-asserted-by":"crossref","unstructured":"Ishibashi K, Kurisu S, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y (2011) Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker. Heart Vessels. doi: 10.1007\/s00380-011-0204-7","DOI":"10.1007\/s00380-011-0204-7"},{"key":"260_CR14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.07590810","volume":"6","author":"F Persson","year":"2011","unstructured":"Persson F, Lewis JB, Rossing P, Hollenberg NK, Parving HH (2011) Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 6:1025\u20131031","journal-title":"Clin J Am Soc Nephrol"},{"key":"260_CR15","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators (2008) Aliskiren combined with losartan in type-2 diabetes and nephropathy. N Engl J Med 358:2433\u20132446","journal-title":"N Engl J Med"},{"key":"260_CR16","doi-asserted-by":"crossref","unstructured":"Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S (2012) Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 13:122\u2013127","DOI":"10.1177\/1470320311422580"},{"key":"260_CR17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","volume":"73","author":"F Persson","year":"2008","unstructured":"Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73:1419\u20131425","journal-title":"Kidney Int"},{"key":"260_CR18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2009.175","volume":"33","author":"S Ito","year":"2010","unstructured":"Ito S, Nakura N, Le Breton S, Keefe D (2010) Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res 33:62\u201366","journal-title":"Hypertens Res"},{"key":"260_CR19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/hr.2010.250","volume":"34","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Nako K, Okamura M, Senda M, Mori T, Ito S (2011) Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res 34:400\u2013401","journal-title":"Hypertens Res"},{"key":"260_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225\u2013232","journal-title":"Kidney Int"},{"key":"260_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/hr.2008.31","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee (2009) The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32:3\u2013107","journal-title":"Hypertens Res"},{"key":"260_CR22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164\u2013176","journal-title":"Diabetes Care"},{"key":"260_CR23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"260_CR24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(99)70442-7","volume":"33","author":"WF Kean","year":"1999","unstructured":"Kean WF, Eknoyan G (1999) Proteinuria, albuminuria, risk, assessment, detection (PARADE): positional paper of the National Kidney Foundation. Am J Kidney Dis 33:1004\u20131010","journal-title":"Am J Kidney Dis"},{"key":"260_CR25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"JV McMurray","year":"2008","unstructured":"McMurray JV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17\u201324","journal-title":"Circ Heart Fail"},{"key":"260_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","volume":"52","author":"DL Feldman","year":"2008","unstructured":"Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DM, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52:130\u2013136","journal-title":"Hypertension"},{"key":"260_CR27","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","volume":"117","author":"NDL Fisher","year":"2008","unstructured":"Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK (2008) Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117:3199\u20133205","journal-title":"Circulation"},{"key":"260_CR28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1291\/hypres.29.997","volume":"29","author":"T Kushiro","year":"2006","unstructured":"Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL (2006) Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 29:997\u20131005","journal-title":"Hypertens Res"},{"key":"260_CR29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","volume":"26","author":"K Andersen","year":"2008","unstructured":"Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 26:589\u2013599","journal-title":"J Hypertens"},{"key":"260_CR30","unstructured":"http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2011\/1572562.shtml"},{"key":"260_CR31","doi-asserted-by":"crossref","unstructured":"Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomn SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA (2012) Baseline characteristics in the aliskiren trial in type 2 diabetes using cardiorenal endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (epub ahead of print)","DOI":"10.1177\/1470320311434818"},{"key":"260_CR32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0002-9343(82)90415-6","volume":"73","author":"SC Textor","year":"1982","unstructured":"Textor SC, Bravo EL, Fouad FM, Tarazi RC (1982) Hyperkalemia in azotemic patients during angiotensin converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73:719\u2013725","journal-title":"Am J Med"},{"key":"260_CR33","doi-asserted-by":"crossref","unstructured":"Kostis JB, Shelton B, Gosselin G, Goulet C, Hood Jr WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfield J, SOLVD Investigators (1996) Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). Am Heart J 131:350\u201355","DOI":"10.1016\/S0002-8703(96)90365-8"},{"key":"260_CR34","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc10-0833","volume":"33","author":"F Persson","year":"2010","unstructured":"Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH, AVOID Study Investigators (2010) Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 33:2304\u20132309","journal-title":"Diabetes Care"},{"key":"260_CR35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CDA, Schalkwijk C, Danser AHJ, Boomsma F, Frandsen E, Parving HH (2009) Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 32:1873\u20131879","journal-title":"Diabetes Care"},{"key":"260_CR36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ackd.2005.01.008","volume":"12","author":"MC Thomas","year":"2005","unstructured":"Thomas MC, Burns WC, Cooper ME (2005) Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12:177\u2013186","journal-title":"Adv Chronic Kidney Dis"},{"key":"260_CR37","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:1773\u20131781","journal-title":"Am J Pathol"},{"key":"260_CR38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","volume":"61","author":"AD Struthers","year":"2004","unstructured":"Struthers AD, MacDonald TM (2004) Review of aldosterone- and angiotensin II induced target organ damage and prevention. Cardiovasc Res 61:663\u2013670","journal-title":"Cardiovasc Res"},{"key":"260_CR39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1291\/hypres.28.447","volume":"28","author":"K Yoshida","year":"2005","unstructured":"Yoshida K, Kim-Mitsuyama S, Wake R, Izumi Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H (2005) Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 28:447\u2013455","journal-title":"Hypertens Res"},{"key":"260_CR40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Shiffrin","year":"2006","unstructured":"Shiffrin EL (2006) Effects of aldosterone on the vasculature. Hypertension 47:312\u2013318","journal-title":"Hypertension"},{"key":"260_CR41","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2005040390","volume":"16","author":"K Miyata","year":"2005","unstructured":"Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16:2906\u20132912","journal-title":"J Am Soc Nephrol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-012-0260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-012-0260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-012-0260-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:09:09Z","timestamp":1559056149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-012-0260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1007\/s00380-012-0260-7","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,23]]}}}